New 'Genesis' for Viragen's Anti-CD55 Cancer Program

Failed biotech Viragen Inc. might have called it quits in 2007, but its monoclonal antibody targeting CD55 was reborn in start-up Genesis Biopharma Inc., which licensed the CD55-related assets earlier this year and plans to move forward with testing in both solid tumors and blood cancers.